Report cover image

Biopharmaceutical Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Type (API, Finished Drug Product), By Product, By Service, By Source, By Workflow, By Therapeutic Area, By End Use, By Region, And Segment

Publisher Grand View Research
Published Oct 06, 2025
Length 120 Pages
SKU # GV20574977

Description

Biopharmaceutical CDMO Market Summary

The global biopharmaceutical contract development and manufacturing organization market size was estimated at USD 25.1 billion in 2024 and is projected to reach USD 56.6 billion by 2033, growing at a CAGR of 9.55% from 2025 to 2033. The industry is driven by increasing demand for biologics, biosimilars, and advanced therapies.

Besides, rising demand for outsourcing services, growing expansion of large product pipeline, and increasing cost effectiveness within CDMO services have led most biopharmaceutical manufacturers to outsource their production capabilities. Most biopharmaceutical companies are developing biologics & biosimilars due to continuous demand for targeted, effective, and personalized therapies, as these offer higher efficacy, reduced side effects, and the ability to address complex & chronic diseases such as cancer, autoimmune disorders, and rare genetic conditions. Besides, the industry has witnessed new growth opportunities due to specialized CDMOs offering greater speed-to-market, expanding patent expiration, and rising need for blockbuster drugs, creating a strong pipeline for biologics and biosimilars, further contributing to market growth. In addition, growing advancements in biotechnology have further lowered production costs and risks. Thus, biologics are currently prioritized for clinical value, commercial potential, and long-term growth prospects.

Biopharmaceuticals manufacturing will be recognized as one of the leading 10 revenue generators in the coming years. Currently, most of the small molecule makes up to 90% of drugs on the market and continue to be the primary active substance in the pharmaceutical industry; however, companies are increasingly shifting their focus to manufacturing and developing highly profitable, highly complex large molecules known as biologics. This has led biopharmaceutical companies to necessitate collaboration with external partners capable of managing advanced manufacturing processes to continuously develop new products to meet the increasing consumer demand, which in turn is anticipated to surge CDMO services. For instance, the International Federation of Pharmaceutical Manufacturers & Associations mentioned that the biopharmaceutical R&D spending is expected to grow to USD 213 million by 2025, owing to the growing demand for biopharmaceutical products. In addition, an expanding number of drug pipelines has significantly contributed to market growth.

Global Biopharmaceutical CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biopharmaceutical contract development and manufacturing organization (CDMO) market report based on type, product, service, source, workflow, therapeutic area, end use, and region:
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • API
  • Finished Drug Product
  • Oral Solid Dose
  • Semi-Solid Dose
  • Liquid Dose
  • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Biologics
  • Monoclonal antibodies (mAbs)
  • Recombinant proteins & enzymes
  • Vaccines
  • Cell & Gene Therapies
  • Nucleic acid Therapeutics
  • Others
  • Biosimilars
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Contract Development
  • Cell Line Development
  • Process Development
 Upstream

 Downstream
  • Analytical Testing & Method Validation
  • Scale-Up & Tech Transfer
  • Contract Manufacturing
  • API Manufacturing
  • Finished Drug Products Manufacturing
  • Packaging and Labelling
  • Regulatory Affairs
  • Logistics & Storage
  • Others
  • Source Outlook (Revenue, USD Million, 2021 - 2033)
  • Mammalian
  • Microbial
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disease
  • Metabolic Disorders
  • Autoimmune Diseases
  • Respiratory Diseases
  • Ophthalmology
  • Gastrointestinal Disorders
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Large Pharma & Biotech Companies
  • Small & Mid-sized Pharma & Biotech Companies
  • Academic Research & Government Institutes
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

120 Pages
Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Product
1.2.3. Service
1.2.4. Source
1.2.5. Workflow
1.2.6. Therapeutic Area
1.2.7. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Top-Down Analysis
1.7.3. Botton-Up Approach
1.7.4. Multivariate Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Biopharmaceutical Contract Development and Manufacturing Organization Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Demand for Biologics & Advanced Therapy
3.2.1.2. Rising Investment In R&D
3.2.1.3. Growing Biopharmaceutical Industry
3.2.2. Market Restraint Analysis
3.2.2.1. Compliance Issues While Outsourcing
3.2.2.2. Changing Scenarios In Developing Countries
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Value Chain Analysis
3.6.1. Supply Trends
3.6.2. Demand Trends
3.7. Market Analysis Tools
3.7.1. Porter’s Five Force Analysis
3.7.2. PESTEL by SWOT Analysis
Chapter 4. Biopharmaceutical Contract Development and Manufacturing Organization Market: Type Estimates & Trend Analysis
4.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Type: Segment Dashboard
4.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Type: Movement Analysis
4.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
4.4. API
4.4.1. API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Finished Drug Product
4.5.1. Finished Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.2. Oral Solid Dose
4.5.2.1. Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.3. Semi-Solid Dose
4.5.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.4. Liquid Dose
4.5.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.5. Others
4.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Biopharmaceutical Contract Development and Manufacturing Organization Market: Product Estimates & Trend Analysis
5.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Product: Segment Dashboard
5.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Product: Movement Analysis
5.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
5.4. Biologics
5.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.2. Monoclonal Antibodies (mAbs)
5.4.2.1. Monoclonal antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.3. Recombinant Proteins & Enzymes
5.4.3.1. Recombinant Proteins & Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.4. Vaccines
5.4.4.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.5. Cell & Gene Therapies
5.4.5.1. Cell & Gene Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.6. Nucleic acid Therapeutics
5.4.6.1. Nucleic Acid Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.7. Others
5.4.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Biosimilars
5.5.1. Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Biopharmaceutical Contract Development and Manufacturing Organization Market: Service Estimates & Trend Analysis
6.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Service: Segment Dashboard
6.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Service: Movement Analysis
6.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
6.4. Contract Development
6.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.2. Cell Line Development
6.4.2.1. Cell Line Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Process Development & Optimization
6.4.3.1. Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3.2. Upstream
6.4.3.2.1. Upstream Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3.3. Downstream
6.4.3.3.1. Downstream Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. Analytical Testing & Method Validation
6.4.4.1. Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.5. Scale-up & Tech Transfer
6.4.5.1. Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Contract Manufacturing
6.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. API Manufacturing
6.5.2.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. Finished drug products Manufacturing
6.5.3.1. Finished drug products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Packaging and Labelling
6.6.1. Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Regulatory Affairs
6.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Logistics & Storage
6.8.1. Logistics & Storage Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.9. Others
6.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Biopharmaceutical Contract Development and Manufacturing Organization Market: Source Estimates & Trend Analysis
7.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Source: Segment Dashboard
7.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Source: Movement Analysis
7.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Source, 2021 - 2033 (USD Million)
7.4. Mammalian
7.4.1. Mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Microbial
7.5.1. Microbial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Biopharmaceutical Contract Development and Manufacturing Organization Market: Workflow Estimates & Trend Analysis
8.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Segment Dashboard
8.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Movement Analysis
8.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
8.4. Clinical
8.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Commercial
8.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Biopharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area Estimates & Trend Analysis
9.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Segment Dashboard
9.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Movement Analysis
9.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
9.4. Oncology
9.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. Infectious Diseases
9.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6. Neurological Disorders
9.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7. Cardiovascular Disease
9.7.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.8. Metabolic Disorders
9.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.9. Autoimmune Diseases
9.9.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.10. Respiratory Diseases
9.10.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.11. Ophthalmology
9.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.12. Gastrointestinal Disorders
9.12.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.13. Others
9.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Biopharmaceutical Contract Development and Manufacturing Organization Market: End Use Estimates & Trend Analysis
10.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Segment Dashboard
10.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Movement Analysis
10.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
10.4. Large Pharma & Biotech Companies
10.4.1. Large Pharma & Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5. Small & Mid-sized Pharma & Biotech Companies
10.5.1. Small & Mid-sized Pharma & Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.6. Academic Research & Government Institutes
10.6.1. Academic Research & Government Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 11. Biopharmaceutical Contract Development And Manufacturing Organization Market: Regional Estimates & Trend Analysis
11.1. Regional Market Dashboard
11.2. Regional Market Share Analysis, 2024 & 2033
11.3. North America
11.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.3.2. U.S
11.3.2.1. Key Country Dynamics
11.3.2.2. Competitive Scenario
11.3.2.3. Regulatory Framework
11.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.3.3. Canada
11.3.3.1. Key Country Dynamics
11.3.3.2. Competitive Scenario
11.3.3.3. Regulatory Framework
11.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.3.4. Mexico
11.3.4.1. Key Country Dynamics
11.3.4.2. Competitive Scenario
11.3.4.3. Regulatory Framework
11.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.4. Europe
11.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.4.2. UK
11.4.2.1. Key Country Dynamics
11.4.2.2. Competitive Scenario
11.4.2.3. Regulatory Framework
11.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.4.3. Germany
11.4.3.1. Key Country Dynamics
11.4.3.2. Competitive Scenario
11.4.3.3. Regulatory Framework
11.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.4.4. France
11.4.4.1. Key Country Dynamics
11.4.4.2. Competitive Scenario
11.4.4.3. Regulatory Framework
11.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.4.5. Italy
11.4.5.1. Key Country Dynamics
11.4.5.2. Competitive Scenario
11.4.5.3. Regulatory Framework
11.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.4.6. Spain
11.4.6.1. Key Country Dynamics
11.4.6.2. Competitive Scenario
11.4.6.3. Regulatory Framework
11.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.4.7. Denmark
11.4.7.1. Key Country Dynamics
11.4.7.2. Competitive Scenario
11.4.7.3. Regulatory Framework
11.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.4.8. Sweden
11.4.8.1. Key Country Dynamics
11.4.8.2. Competitive Scenario
11.4.8.3. Regulatory Framework
11.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.4.9. Norway
11.4.9.1. Key Country Dynamics
11.4.9.2. Competitive Scenario
11.4.9.3. Regulatory Framework
11.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.5. Asia Pacific
11.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.5.2. Japan
11.5.2.1. Key Country Dynamics
11.5.2.2. Competitive Scenario
11.5.2.3. Regulatory Framework
11.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.5.3. China
11.5.3.1. Key Country Dynamics
11.5.3.2. Competitive Scenario
11.5.3.3. Regulatory Framework
11.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.5.4. India
11.5.4.1. Key Country Dynamics
11.5.4.2. Competitive Scenario
11.5.4.3. Regulatory Framework
11.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.5.5. Australia
11.5.5.1. Key Country Dynamics
11.5.5.2. Competitive Scenario
11.5.5.3. Regulatory Framework
11.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.5.6. Thailand
11.5.6.1. Key Country Dynamics
11.5.6.2. Competitive Scenario
11.5.6.3. Regulatory Framework
11.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.5.7. South Korea
11.5.7.1. Key Country Dynamics
11.5.7.2. Competitive Scenario
11.5.7.3. Regulatory Framework
11.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.6. Latin America
11.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.6.2. Brazil
11.6.2.1. Key Country Dynamics
11.6.2.2. Competitive Scenario
11.6.2.3. Regulatory Framework
11.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.6.3. Argentina
11.6.3.1. Key Country Dynamics
11.6.3.2. Competitive Scenario
11.6.3.3. Regulatory Framework
11.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.7. MEA
11.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.7.2. South Africa
11.7.2.1. Key Country Dynamics
11.7.2.2. Competitive Scenario
11.7.2.3. Regulatory Framework
11.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.7.3. UAE
11.7.3.1. Key Country Dynamics
11.7.3.2. Competitive Scenario
11.7.3.3. Regulatory Framework
11.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.7.4. Saudi Arabia
11.7.4.1. Key Country Dynamics
11.7.4.2. Competitive Scenario
11.7.4.3. Regulatory Framework
11.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.7.5. Kuwait
11.7.5.1. Key Country Dynamics
11.7.5.2. Competitive Scenario
11.7.5.3. Regulatory Framework
11.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.7.6. Qatar
11.7.6.1. Key Country Dynamics
11.7.6.2. Competitive Scenario
11.7.6.3. Regulatory Framework
11.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
11.7.7. Oman
11.7.7.1. Key Country Dynamics
11.7.7.2. Competitive Scenario
11.7.7.3. Regulatory Framework
11.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 12. Competitive Landscape
12.1. Key Participant Categorization
12.1.1. Market Leaders
12.1.2. Emerging Players
12.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
12.3. Company Profiles
12.3.1. Lonza Group
12.3.1.1. Company Overview
12.3.1.2. Financial Performance
12.3.1.3. Service Benchmarking
12.3.1.4. Strategic Initiatives
12.3.2. Thermo Fisher Scientific
12.3.2.1. Company Overview
12.3.2.2. Financial Performance
12.3.2.3. Service Benchmarking
12.3.2.4. Strategic Initiatives
12.3.3. Catalent Pharma Solutions
12.3.3.1. Company Overview
12.3.3.2. Financial Performance
12.3.3.3. Service Benchmarking
12.3.3.4. Strategic Initiatives
12.3.4. Samsung Biologics
12.3.4.1. Company Overview
12.3.4.2. Financial Performance
12.3.4.3. Service Benchmarking
12.3.4.4. Strategic Initiatives
12.3.5. WuXi Biologics / WuXi AppTec
12.3.5.1. Company Overview
12.3.5.2. Financial Performance
12.3.5.3. Service Benchmarking
12.3.5.4. Strategic Initiatives
12.3.6. Boehringer Ingelheim (Biopharma CDMO)
12.3.6.1. Company Overview
12.3.6.2. Financial Performance
12.3.6.3. Service Benchmarking
12.3.6.4. Strategic Initiatives
12.3.7. Fujifilm Diosynth Biotechnologies
12.3.7.1. Company Overview
12.3.7.2. Financial Performance
12.3.7.3. Service Benchmarking
12.3.7.4. Strategic Initiatives
12.3.8. Charles River Laboratories
12.3.8.1. Company Overview
12.3.8.2. Financial Performance
12.3.8.3. Service Benchmarking
12.3.8.4. Strategic Initiatives
12.3.9. AGC Biologics
12.3.9.1. Company Overview
12.3.9.2. Financial Performance
12.3.9.3. Service Benchmarking
12.3.9.4. Strategic Initiatives
12.3.10. Siegfried Holding
12.3.10.1. Company Overview
12.3.10.2. Financial Performance
12.3.10.3. Service Benchmarking
12.3.10.4. Strategic Initiatives
12.3.11. Recipharm
12.3.11.1. Company Overview
12.3.11.2. Financial Performance
12.3.11.3. Service Benchmarking
12.3.11.4. Strategic Initiatives
12.3.12. Millipore Sigma (Merck KGaA)
12.3.12.1. Company Overview
12.3.12.2. Financial Performance
12.3.12.3. Service Benchmarking
12.3.12.4. Strategic Initiatives
12.3.13. Biocon Biologics
12.3.13.1. Company Overview
12.3.13.2. Financial Performance
12.3.13.3. Service Benchmarking
12.3.13.4. Strategic Initiatives
12.3.14. Sandoz
12.3.14.1. Company Overview
12.3.14.2. Financial Performance
12.3.14.3. Service Benchmarking
12.3.14.4. Strategic Initiatives
12.3.15. Rentschler Biopharma SE
12.3.15.1. Company Overview
12.3.15.2. Financial Performance
12.3.15.3. Service Benchmarking
12.3.15.4. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us